ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results, Beats Estimates By $0.52 EPS

Key Points

• ANI Pharmaceuticals reported quarterly EPS of $2.70, beating the $2.18 consensus estimate, while revenue rose 27.6% year over year to $290.78 million, also ahead of forecasts.
• The company raised 2026 adjusted EBITDA and EPS guidance, but cut its Cortrophin Gel revenue outlook to $480 million–$500 million, citing fulfillment constraints and slower patient onboarding.
• ANI made a $560 million all-cash offer for Egetis Therapeutics to expand its rare-disease portfolio; the deal could add a product with peak sales potential above $300 million, but is expected to dilute adjusted EPS in its first year.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) posted its earnings results on Thursday. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.18 by $0.52, FiscalAI reports. The business had revenue of $290.78 million for the quarter, compared to analyst estimates of $280.26 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals's revenue was up 27.6% compared to the same quarter last year. During the same period last year, the business posted $2.04 EPS.

Here are the key takeaways from ANI Pharmaceuticals' conference call:

• ANI reported third-quarter revenue of $290.8 million, up 28% year over year, and adjusted EBITDA of $83.3 million, up 40%; adjusted diluted EPS rose to $2.70. Generics revenue increased 11% to $104.5 million, while ILUVIEN revenue grew 34% to $22.3 million.
• Cortrophin Gel revenue was $138.7 million, below expectations, as specialty-pharmacy capacity constraints and slower onboarding at new gout prescribers delayed conversion of cases to patients on therapy. ANI cut 2026 Cortrophin guidance to $480 million–$500 million from $520 million–$540 million, while citing strong demand and steps to improve fulfillment.
• ANI updated 2026 total revenue guidance to $1.085 billion–$1.125 billion and raised adjusted EBITDA guidance to $290 million–$300 million and adjusted EPS guidance to $9.37–$9.71; ILUVIEN guidance also increased to $80 million–$85 million. The company said strong profitability and favorable product mix support the higher earnings outlook.
• ANI announced an all-cash offer for Egetis Therapeutics valuing its equity at $560 million, adding EMCITATE, the first approved treatment for MCT8 deficiency, to its rare-disease portfolio. ANI sees peak annual sales potential above $300 million and expects to leverage its commercial infrastructure, though the deal is expected to dilute adjusted EPS in year one and raise pro forma net leverage to about 2.7x.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded down $2.03 during trading hours on Thursday, hitting $69.62. 1,295,657 shares of the company traded hands, compared to its average volume of 334,087. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of 15.00, a P/E/G ratio of 2.31 and a beta of 0.45. ANI Pharmaceuticals has a twelve month low of $68.79 and a twelve month high of $95.45. The firm has a 50-day moving average of $72.65 and a 200 day moving average of $77.41. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of recent analyst reports. Guggenheim decreased their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a report on Monday, August 10th. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Oppenheimer initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 price objective for the company. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an "outperform" rating and a $104.00 target price for the company. Finally, Canaccord Genuity Group lowered their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a report on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $99.60.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Jeanne Thoma sold 1,000 shares of the firm's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $71.53, for a total value of $71,530.00. Following the sale, the director directly owned 26,762 shares in the company, valued at $1,914,285.86. This trade represents a 3.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $71.89, for a total transaction of $388,206.00. Following the transaction, the chief executive officer owned 333,689 shares in the company, valued at approximately $23,988,902.21. The trade was a 1.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 30,412 shares of company stock valued at $2,220,970 in the last quarter. Company insiders own 8.10% of the company's stock.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q3 adjusted earnings were $2.70 per share, above the roughly $2.18 analyst consensus and up from $2.04 a year earlier. Revenue of $290.78 million also topped estimates of about $280 million and increased 27.6% year over year. ANI Pharmaceuticals Q3 results
• Neutral Sentiment: ANI proposed a recommended public offer for Swedish biotech Egetis Therapeutics valued at SEK 5.6 billion (about $560 million). ANI says the acquisition would expand the scale and scope of its rare-disease business; its ultimate impact will depend on completion and the value generated. ANI offer for Egetis Therapeutics
• Negative Sentiment: The acquisition’s substantial price may raise concerns about funding, integration and execution, potentially weighing on shares even as quarterly results beat expectations. ANI offers $560 million for Egetis

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI's portfolio includes branded products and generic medicines, as well as treatments for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.